X

Trial Profile

Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Reslizumab (Primary) ; Corticosteroids; Prednisone
Indications Churg-Strauss syndrome
Focus Adverse reactions
Acronyms RITE

Most Recent Events

03 Feb 2021 Results published in the Annals of Allergy, Asthma and Immunology
03 Feb 2021 Status has been changed to completed as per results published in the Annals of Allergy, Asthma and Immunology.
12 Sep 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com